Quagen Pharmaceuticals LLC Importer Application for Diphenoxylate
Summary
The DEA published a notice that Quagen Pharmaceuticals LLC applied on March 4, 2026 to be registered as an importer of Diphenoxylate (Schedule II controlled substance, Drug Code 9170). Comments and objections may be submitted through May 18, 2026. The company plans to import the controlled substance for distribution to its customers.
“Quagen Pharmaceuticals LLC, 37 Fairfield Place, West Caldwell, New Jersey 07006, applied to be registered as an importer of the following basic class(es) of controlled substance(s)”
About this source
GovPing monitors Regs.gov: Drug Enforcement Administration for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 30 changes logged to date.
What changed
The DEA published a notice that Quagen Pharmaceuticals LLC applied on March 4, 2026 to be registered as an importer of Diphenoxylate (Schedule II controlled substance, Drug Code 9170). The application is subject to public comment and objection until May 18, 2026. Registered bulk manufacturers of the affected controlled substance class or applicants may submit comments, file objections, or request a hearing on the proposed registration.
Affected parties include registered bulk manufacturers of Schedule II controlled substances and applicants for similar importer registrations. Authorization for this registration does not extend to the import of FDA-approved or non-approved finished dosage forms for commercial sale. The notice is published pursuant to 21 CFR 1301.34(a) and is part of the DEA's standard importer registration process.
Archived snapshot
Apr 22, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
Content
ACTION:
Notice of application.
SUMMARY:
Quagen Pharmaceuticals LLC has applied to be registered as an importer of basic class(es) of controlled substance(s). Refer
to
SUPPLEMENTARY INFORMATION
listed below for further drug information.
DATES:
Registered bulk manufacturers of the affected basic class(es), and applicants, therefore, may submit electronic comments on
or objections to the issuance of the proposed registration on or before May 18, 2026. Such persons may also file a written
request for a
hearing on the application on or before May 18, 2026.
ADDRESSES:
The Drug Enforcement Administration requires that all comments be submitted electronically through the Federal eRulemaking
Portal, which provides the ability to type short comments directly into the comment field on the web page or attach a file
for lengthier comments. Please go to https://www.regulations.gov and follow the online instructions at that site for submitting comments. Upon submission of your comment, you will receive
a Comment Tracking Number. Please be aware that submitted comments are not instantaneously available for public view on https://www.regulations.gov. If you have received a Comment Tracking Number, your comment has been successfully submitted and there is no need to resubmit
the same comment. All requests for a hearing must be sent to: (1) Drug Enforcement Administration, Attn: Hearing Clerk/OALJ,
8701 Morrissette Drive, Springfield, Virginia 22152; and (2) Drug Enforcement Administration, Attn: DEA Federal Register Representative/DPW,
8701 Morrissette Drive, Springfield, Virginia 22152. All requests for a hearing should also be sent to: Drug Enforcement Administration,
Attn: Administrator, 8701 Morrissette Drive, Springfield, Virginia 22152.
SUPPLEMENTARY INFORMATION:
In accordance with 21 CFR 1301.34(a), this is notice that on March 4, 2026, Quagen Pharmaceuticals LLC, 37 Fairfield Place,
West Caldwell, New Jersey 07006, applied to be registered as an importer of the following basic class(es) of controlled substance(s):
| Controlled substance | Drug code | Schedule |
|---|---|---|
| Diphenoxylate | 9170 | II |
The company plans to import the listed controlled substance for distribution to its customer. No other activities for these
drug codes are authorized for this registration.
Approval of permit applications will occur only when the registrant's business activity is consistent with what is authorized
under 21 U.S.C. 952(a)(2). Authorization will not extend to the import of Food and Drug Administration-approved or non-approved
finished dosage forms for commercial sale.
Thomas Prevoznik, Deputy Assistant Administrator. [FR Doc. 2026-07559 Filed 4-16-26; 8:45 am] BILLING CODE 4410-09-P
Download File
CFR references
Mentioned entities
Citations
Parties
Related changes
Get daily alerts for Regs.gov: Drug Enforcement Administration
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from DEA.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when Regs.gov: Drug Enforcement Administration publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.